Clinical trials: Levodopa
Parkinson's Disease
A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients
To investigate the safety of once-daily repeated transdermal administration of SPM 962 within a dose range of 4.5 to 36.0 mg/day (54-week treatment period) in Parkinson's disease (PD) patients treated concomitantly with L-dopa in…
- Trial name
- NCT01631825
- Testing
- SPM 962
- Where
- 8 sites in Japan
- Volunteers
- 321 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Dyskinesia, Drug-Induced, Parkinson Disease
Safinamide for Levodopa-induced Dyskinesia (PD-LID)
This will be a prospective, multi-center, randomized, double-blind, parallel group, placebo-controlled study, in participants with PD who are on a stable regimen of dopaminergic medication and have at least mild levodopa-induced…
- Trial name
- NCT03987750
- Testing
- Safinamide Methanesulfonate 150mg, Safinamide Methanesulfonate 100mg
- Sponsor
- Zambon SpA
Parkinson's Disease
The Effect Of E2007 On Pharmacodynamic Responses To Levodopa Among Patients With Parkinson's Disease Who Experience Dyskinesia And Motor Fluctuations
A randomized, double blind, placebo-controlled study employing a mixed parallel group and fixed sequence cross-over design. Patients will be randomized to one of two treatment groups ('E2007' or 'Placebo') in a 1:1 ratio and…
- Trial name
- NCT00451633
- Testing
- E2007
- Where
- 5 sites in Germany, Italy
- Sponsor
- Eisai Inc.
Parkinson's Disease
Post Market (Libra/LibraXP System) Deep Brain Stimulation (DBS) Parkinson's Disease Study
The objective of this study is to evaluate the effectiveness of Deep Brain Stimulation as an adjunctive treatment for reducing some of the symptoms of advanced, levodopa-responsive Parkinson's disease that are not adequately…
- Trial name
- NCT01352819
- Where
- 6 sites in France, Germany and 1 more
- Volunteers
- 21 people
- Sponsor
- Abbott Medical Devices
Parkinson's Disease (PD)
Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide
To investigate the effect of three single oral doses of BIA 9-1067 (25 mg, 50 mg and 100 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of controlled-release levodopa 100 mg/benserazide…
- Trial name
- NCT02169466
- Testing
- BIA 9-1067, Madopar® HBS
- Where
- Portugal
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease
Effects of PR Oxycodone and of Levodopa, vs Placebo, on Central Neuropathic Pain in Parkinson's Disease
This study will be conducted in three parallel groups receiving oxycodone, levodopa or placebo, administered as an add-on therapy, in addition to the usual antiparkinsonian treatment.
- Trial name
- OXYDOPA (NCT02601586)
- Testing
- PR Oxycodone, Levodopa
- Where
- 18 sites in France
- Volunteers
- 67 people
- Sponsor
- University Hospital, Toulouse
Parkinson's Disease
Phase 2 Clinical Study of KW-6500 in Parkinson's Disease Patients With Motor Response Complication on Levodopa Therapy
The purpose of this study is to evaluate the efficacy of KW-6500 versus placebo when administered as a subcutaneous injection at the individualized maintenance dose level in an OFF state in Parkinson's disease patients with motor…
- Trial name
- NCT00610103
- Testing
- apomorphine hydrochloride
- Where
- 4 sites in Japan
- Volunteers
- 16 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Parkinson Disease
Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia
Mesdopetam (IRL790) is an experimental small molecule compound with psychomotor stabilizing properties. The primary target is the dopamine D3 receptor, a target implicated in the generation of levodopa-induced dyskinesia, a…
- Trial name
- NCT03368170
- Testing
- Mesdopetam (IRL790)
- Where
- 20 sites in Sweden, United Kingdom
- Volunteers
- 75 people
- Sponsor
- Integrative Research Laboratories AB
Pharmacokinetics
Pharmacokinetic Study With Repeated Doses of Stalevo
The purpose of this study is to show that higher minimum concentration values are obtained following repeated doses of Stalevo 4 times daily compared to lecodopa/carbidopa treatment with corresponding dosing regimen.
- Trial name
- NCT00693862
- Testing
- levodopa, carbidopa, entacapone, levodopa, carbidopa
- Where
- 3 sites in Finland
- Volunteers
- 19 people
- Sponsor
- Orion Corporation, Orion Pharma
Healthy Volunteers
Fasting Comparative Bioavailability of Two Tablet Formulations of Levodopa /Benserazide in Healthy Volunteers
A group of 24 healthy volunteers receive one tablet of an association of levodopa 200 mg and benserazide 50 mg corresponding to two drug products: a test formulation (Evoser ®; Phoenix S.A.I.C.
- Trial name
- PHOE10903 (NCT01327261)
- Testing
- Levodopa + benserazide
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Buenos Aires
Advanced Parkinson's Disease
A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian Medications
The primary objective of this study is to measure the efficacy of ABT-SLV187 in subjects with advanced Parkinson's disease.
- Trial name
- NCT01960842
- Testing
- Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube
- Volunteers
- 31 people
- Sponsor
- AbbVie
Parkinson Disease
How the Loss of Dopamine and Dopamine-Restoring Medicines Affect Movement Performance
This study has two purposes: 1) to understand the effect of a decline of dopamine in the brain during normal aging and in patients with Parkinson's disease, and 2) to investigate how medicines used to treat Parkinson's disease…
- Trial name
- NCT00040196
- Where
- United States
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Parkinson's Disease
VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)
The objective of this study is to assess the safety of VY-AADC02 in participants with Parkinson's disease (PD) with motor fluctuations.
- Trial name
- NCT03562494
- Testing
- VY-AADC02
- Where
- 11 sites in United States
- Volunteers
- 14 people
- Sponsor
- Neurocrine Biosciences
Parkinson Disease
Personality, as a Predictive Factor of Therapeutic Response on Quality of Life After Continuous Perfusion of Dopaminergic Drugs, in Parkinson's Disease
The aim of the study is to evaluate if patients' personality could be considerate as predictive factor of quality of life after the establishment of continuous infusion of dopaminergic treatments to observe if there are…
- Trial name
- PSYCHO-PERF (NCT03793491)
- Testing
- TCI scale, PDQ-39 scale
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Toulouse
Parkinson's Disease
A Study of MK0657 in Parkinson's Disease Patients (0657-006)
In this clinical trial, the safety of MK0657 when given with levodopa will be assessed in patients with Parkinson's Disease. This study will also measure the effectiveness of MK0657, when given in combination with levodopa, to…
- Trial name
- NCT00505843
- Testing
- MK0657, Comparator: levodopa, Comparator: carbidopa
- Volunteers
- 18 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson's Disease
Topiramate as a Treatment for Levodopa-Induced Dyskinesia in Parkinson's Disease
A phase II double blind trial to evaluate the effects of the AMPA, glutamte antagonist, topiramate on levodopa-induced dyskinesia in Parkinson's disease
- Trial name
- NCT00296959
- Testing
- topiramate (drug)
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Parkinson's Disease
Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
Randomised, double-blind, double dummy, parallel group design. Following the screening period patients will be randomised at the baseline visit, in a 1:1:1 manner, to one of three treatment arms; 4 mg E2007, 200 mg entacapone…
- Trial name
- NCT00360308
- Testing
- E2007
- Where
- France
- Volunteers
- 723 people
- Sponsor
- Eisai Limited
Parkinson Disease (PD), Parkinson's Disease
Real-world Patient Experiences With Inbrija®
Parkinson's disease can cause OFF episodes, when medication effects wear off and symptoms return, affecting movement, daily activities, comfort, and wellbeing.
- Conditions
- Parkinson Disease (PD), Parkinson's Disease, Off Episodes of Parkinson Disease
- Trial name
- INHALE-PD (NCT07797790)
- Testing
- Levodopa inhalation powder
- Where
- 2 sites in Austria
- Volunteers
- 120 people
- Sponsor
- Merz Therapeutics GmbH
Smoking
A Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking Adults
This is an open label, parallel group study to evaluate the pharmacokinetics (PK) and safety of a single dose of CVT-301 in smoking and non-smoking adults.
- Trial name
- NCT02633839
- Testing
- CVT-301, Carbidopa
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Acorda Therapeutics
Visual Attention in Parkinson's Disease
Visual Selective Attention in Parkinson's Disease
Parkinson's disease (PD), which is generally considered to be a motor disorder, is now known to be accompanied in many instances by a variety of cognitive defects.
- Trial name
- VSA-PD (NCT01135407)
- Testing
- Recording during computerized tests
- Where
- France
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble